| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 91.06 KB | Adobe PDF |
Autores
Orientador(es)
Resumo(s)
We report a patient with severe psoriasis who failed to respond to phototherapy, conventional systemic treatment and four biologic agents (etanercept, ustekinumab, adalimumab and secukinumab). Combination of a higher-dose secukinumab regimen with phototherapy had no success. Remarkably, ixekizumab, an IL-17A inhibitor, provided almost complete psoriasis clearance after 24 weeks of treatment. The reason for the success of ixekizumab after the failure to respond to a biologic with same mechanism of action is still unknown. Interestingly, failure of secukinumab does not preclude future therapeutic success with a second IL-17A-inhibitor.
Descrição
Palavras-chave
Contexto Educativo
Citação
Dermatol Online J. 2018 Sep 10;24(9). pii: 13030/qt2qn1p4bz
Editora
University of California Davis
